Induction of robust type-1 CD8(+) T-cell responses in WHO grade II low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC

PURPOSE: WHO grade II low-grade gliomas (LGGs) with high risk factors for recurrence are mostly lethal despite current treatments. We conducted a phase I study to evaluate the safety and immunogenicity of subcutaneous vaccinations with synthetic peptides for glioma-associated antigen (GAA) epitopes...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Okada, Hideho, Butterfield, Lisa H., Hamilton, Ronald L., Hoji, Aki, Sakaki, Masashi, Ahn, Brian J., Kohanbash, Gary, Drappatz, Jan, Engh, Johnathan, Amankulor, Nduka, Lively, Mark O., Chan, Michael D., Salazar, Andres M., Shaw, Edward G., Potter, Douglas M., Lieberman, Frank S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297523/
https://ncbi.nlm.nih.gov/pubmed/25424847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1790
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados